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Challenges and inequalities of opportunities in European psychiatry research: 
The example of psychodiagnostic tool availability in 
research on early autism identification 
 
Summary 
Background: Europe is diverse in terms of economy, cultures, socio-demography and 
languages. A crucial aspect of psychiatric research is the availability of standardized 
screening, diagnostic and characterization instruments. Aims/Method: We fine-mapped the 
accessibility of 14 clinical scales and cognitive tests for the assessment of early childhood 
autism spectrum disorder [ASD] (e.g. ADOS, ADI-R, SCQ, SRS, CHAT, MESL) within 21 
European countries. These tools are essential for internationally competitive early ASD 
detection research. Results: We identified a considerable variation not only in the availability, 
but also psychometric standardization, and formal distribution of the instruments between the 
countries, privileging English speaking, high-income and highly populated European 
countries. Absence of country-specific standardization was a problem across many countries, 
independent of income and size. Discussion: Findings demonstrate, on a concrete level, the 
challenges in creating equal early ASD identification research opportunities in Europe, and 
the need for increased funding for instrument development and validation. We discuss the 
reasons, implications and consequences of this inequity and ways of reducing it. 
 
Key Words: Assessment, neurodevelopmental disorders, mental health, tests, 
psychometrics 
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Introduction 
Europe is diverse in terms of cultures and languages, comprising 53 countries 
according to the WHO definition (including parts of geographical Asia), of which 28 are 
currently organized under the European Union (EU). Although many European countries are 
developed high-income countries, this should not camouflage the huge differences between 
high and less developed countries. For instance, following the World Bank’s (worldbank.org) 
2013/14 classification of low and middle income (LAMI) countries, a noteworthy number of 
17 European countries are still judged as low-middle (e.g. Albania, Georgia, Moldova, 
Ukraine) or upper-middle income (e.g. Bulgaria, FYR Macedonia, Romania, Turkey), of 
which 4 are EU countries. Clinical and research psychiatry is equally diverse across Europe, 
with substantial variations even within countries due to federalism or regionalization (Evans-
Lacko et al., 2014; Muijen, 2012). As for the world-wide situation, research output in Europe 
is dominated by the high-income countries (Muijen, 2012; Sumathipala et al., 2004). 
ASD is a neurodevelopmental condition defined by overarching impairments in the 
areas of reciprocal social communication and interaction, alongside a preference for 
repetitive, stereotyped activities, patterns of behaviors and interests (Bölte & Hallmayer, 
2011). ASD has emerged a top priority health care issue in many countries (see for instance 
USA: “Combating Autism Act of 2006”, “Autism Treatment Acceleration ACT of 2009”; or 
UK: Autism Act UK, 2009) because of increasing rates of diagnoses (in high income 
countries) around the globe (Elsabbagh et al., 2012), as well as high associated societal 
challenges and costs (Gustavsson et al., 2011) of educational and clinical care. In recent years, 
a growing interest in early detection of ASD has emerged, mostly driven by the insight that 
early identification is a prerequisite for early intervention, which itself may improve long-
term outcomes for individuals with ASD (Dawson, 2008). Several methodologies have helped 
to investigate early detection and intervention in ASD, in particular screening studies and 
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research on high-risk siblings (Bölte et al., 2013; Garcia-Primo et al., 2014; Ozonoff et al., 
2011). 
The availability of standardized diagnostic instruments is a crucial prerequisite for 
conducting high-quality early ASD detection research. Without evidence-based standardized 
phenotyping in psychiatry there is a risk of diagnostic bias and “garbage in, garbage out” 
research. Significant progress has been made over the past two decades in the development of 
reliable and valid phenotyping tools for ASD (Charman & Gotham, 2013). Many of these 
instruments are part of national or regional clinical guidelines for ASD in European countries 
(Arngrim et al., 2013; "Autism diagnosis in children and young people. Recognition, referral 
and diagnosis of children and young people on the autism spectrum,"), while some are viewed 
as a “gold standard”, most notably the Autism Diagnostic Observation Schedule, Second 
Edition (Hus, Gotham, & Lord, 2012) combined with the Autism Diagnostic Interview- 
Revised (Rutter, Le Couteur, & Lord, 2003). Publication of ASD research findings in leading 
ASD or general psychiatry journals can be challenging or even impossible without these tools. 
Nevertheless, their availability, validation and standardization are limited to a small group of 
languages and cultures. The latter substantially limits international collaboration, and research 
opportunities for many countries, even in Europe, perhaps particularly for the LAMI countries 
among them. 
The goal of this study was to inventory the accessibility and standardization of 
diagnostic instruments for early identification of autism across 21 European countries. 
Instruments were mapped that are currently required for internationally competitive early 
ASD identification research. With this work we aim to highlight potential challenges and (in-
)equalities of science opportunities across Europe in a concrete manner. The findings might 
be valuable to further raise awareness of research barriers in Europe and beyond, and to direct 
the focus of international public policy on these issues. This is particularly important for 
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LAMI countries, but also for less populated countries and those with less commonly spoken 
languages. 
 
Methods 
Participants and procedure 
The study was carried-out between November 2013 and April 2014. Twenty-one 
European countries involved in the COST (European Cooperation in Science and Technology; 
www.cost.eu) action “Enhancing the Scientific Study of Early Autism” (ESSEA; for details 
see www.cost-essea.com) participated. COST-ESSEA is a network of over 60 scientists from 
23 European countries, including three LAMI countries (Romania, FYR Macedonia, and 
Turkey), intending to develop capacity in early autism research across all action members. 
The principal investigators or research groups’ contact persons for each of the COST ESSEA 
research network countries were surveyed. They were the official COST ESSEA management 
committee representatives for their countries1, chosen by the chair, vice chair and the four 
working group leaders of the action based when a country entered the network based on 
documented scientific experience and excellence in the area of early ASD assessment 
research. The countries were partly clustered for the study to form 16 language/cultural 
groups that in practice usually use the same versions of adapted diagnostic tools: 
Austria/Germany/Switzerland (German), Belgium/The Netherlands (Dutch), Czech Republic, 
Finland, France (including information on French-Canadian adaptations of tools), Hungary, 
Iceland, Italy, Israel, Macedonia, Poland, Portugal (including information on Brazilian 
adaptations of tools), Spain, Sweden/Norway (Scandinavia), Romania, and UK/Ireland 
(English; even US-versions of instruments included here). Excel spreadsheet inventories 
containing items about the availability and standardization of language/culturally adapted 
                                                          
1 See: https://e-services.cost.eu/w3/index.php?id=1627&action_number=BM1004 
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versions of diagnostic instruments often used in leading research on early ASD identification 
were generated. They included 4 items: (1) Existence of domestic (language) versions of the 
instruments, (2) Domestic psychometric data (norms, reliability, validity) published, (3) 
Copyright for the instrument, (4) Published studies, on each of the 14 scales/tests (see section 
“inventoried instruments” below). The spreadsheets were sent via e-mail to the principal 
investigators or research groups’ contact persons and returned electronically. The returned 
material was analyzed, missing or inconsistent data was added or corrected by the authors 
based on own knowledge, searches in existing databases (e.g. Pubmed, PsychInfo), 
correspondence with publishers as well the original authors of the mapped diagnostic tools, 
and summarized to form an overview on the availably of the clinical scales and psychological 
tests across the 16 language/cultural groups. Finally, the overview was sent to the informants 
for approval. Before submission (December 2014) of this article some information was 
updated to include the most recent developments. 
The selection of early ASD diagnostic instruments was based on a research protocol 
developed within “European Autism Interventions - A Multicentre Study for Developing New 
Medications (EU-AIMS; www.eu-aims.eu). Herein, and using Delphi method, leading 
European labs of ASD research have agreed on a common protocol of 14 clinical scales and 
psychological tests currently deemed the most adequate ones for research on early ASD 
detection, owing to their scientific quality, as well as scientific and clinical usage from an 
international perspective. An overview of this shared protocol is available online 
(www.eurosibs.eu), and the strategic concepts of EU-AIMS in terms of assessments and 
patient characterization are described elsewhere in detail (Ashwood, Buitelaar, Murphy, 
Spooren, & Charman, 2014). The instruments are briefly introduced in the following section. 
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Inventoried instruments 
ASD-specific scales. (1) The Autism Diagnostic Observation Schedule, Second 
Edition (ADOS-2) is a play and interview-based observation scale administered by 
experienced and specifically trained clinicians operationalizing DSM-IV/DSM-5 criteria for 
ASD in an empirically derived diagnostic algorithm. Different modules of the instrument are 
applied depending on the individual’s age and expressive language level. Module T (for 
toddlers; no speech to single phrases, age 12-30 months) and module 1 (no speech to single 
phrases, >31 months of age to school age) are most relevant to early ASD assessment 
research; (2) The Autism Diagnostic Interview-Revised (ADI-R) is an investigator-based 
structured diagnostic caregiver interview, also operationalizing DSM-IV/DSM-5 criteria for 
ASD in a diagnostic algorithm. It can be used for individuals with suspected ASD of any age, 
although it is preferably used for children and adolescents. Recently, specific ADI-R 
diagnostic algorithms for toddlers and preschoolers have been published (Kim, Thurm, 
Shumway, & Lord, 2013). The combined use of the ADI-R and ADOS is often viewed as the 
first choice of diagnosing ASD in research and practice. This is true even for early ASD 
assessments (Zander, Sturm, & Bölte, 2014); (3) The Social Communication Questionnaire 
(SCQ) is a parent-report clinical ASD screener derived from the ADI-R. There are two 
versions: the “current” and the “lifetime” version; (4) The Social Responsiveness Scale (SRS) 
is a parent or teacher report questionnaire of autism traits for children aged 4-18 years. The 
preschool version of the SRS (SRS-P) covers the age range of 3 to 4 years; (5) The 
Development and Well-Being Assessment (DAWBA) is a group of interviews, questionnaires 
and rating scales to enable ICD-10/DSM-IV psychiatric diagnoses on 5-17 year olds; 
DAWBA results can be inserted into a computer program algorithm that generates 
probabilities for a range of psychiatric disorders, including ASD. The provisional computer-
generated diagnoses are then reviewed by an expert clinician; (6) The Quantitative (Q)-CHAT 
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and the Modified (M)-CHAT/-Revised are early parent-report ASD screeners for young 
children aged between 16/18 to 24/30 months of age; (7) The Repetitive Behavior Scale 
(RBS) is a questionnaire that captures the breadth of stereotypic behaviors in individuals of 
any age with ASD on five dimensions, namely ritualistic/sameness behavior, stereotypic 
behavior, self-injurious behavior, compulsive behavior, and restricted interests. For 
comprehensive references see “Supplementary Materials”. 
Non ASD-specific psychological tests and clinical scales. (8) The MacArthur-Bates 
Communicative Development Inventory (CDI) is a parent-/caregiver report tool for assessing 
language and communication development in infants and children. In most versions, it comes 
in two scales, an infant (8 to 16 months), and a toddler scale (16 to 30 months), capturing 
comprehension, word production and aspects of symbolic and communicative gesture, word 
production and the early grammar. Short screening version exists for English and Spanish and 
several other languages; (9) The Mullen Scales of Early Learning is a clinician administered 
child development test to measure gross and fine motor, visual reception, and expressive and 
receptive language from birth to 68 months of age; (10) The Vineland Adaptive Behavior 
Scales (VABS) is a parent/caregiver report measure (administered as either a questionnaire or 
a clinical interview) of adaptive function in everyday life regarding social, communicative, 
daily living and motor skills (up to 6 years) from birth onwards; (11) The Infant-Toddler 
Sensory Profile (ITSP) is a parent/caregiver questionnaire on sensory processing patterns in 
infants (0-6 months) and toddlers (7-36 months), quantifying five domains: auditory, visual, 
tactile, vestibular, and oral sensory processing; (12) The Infant Behavior Questionnaire-
Revised (IBQ-R) is a parent rated measure of infant temperament (3-12 months) on 14 
subscales (e.g. activity level, distress to limitations, fear, smiling/laughter, cuddliness). Short 
and very short versions exist; (13) The Early Childhood Behavior Questionnaire (ECBQ) 
serves the same purpose as the IBQ-R, but in young children aged 18 and 36 months. It 
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ECBQ assesses 18 dimensions of temperament (e.g. attentional focus, cuddliness, discomfort, 
frustration, impulsivity, shyness); (14) The Child Behavior Checklist (CBCL) 1½ -5 is an 
assessment of general problem behaviors in preschool children. The information is obtained 
from parents or teachers using items on eight syndrome scales (emotionally reactive; 
anxious/depressed; somatic complaints; withdrawn; sleep problems, attention problems; rule-
breaking behavior; aggressive behavior). For comprehensive references see “Supplementary 
Materials”. 
 
Results 
A detailed description of adaptations available for each of the reviewed scales or tests 
per country / linguistic region is provided in the supplementary tables and references (Suppl. 
Tables 1-14 & references): ADOS in Supplementary Table 1, ADI-R in Supplementary Table 
2, SCQ in Supplementary Table 3, SRS in Supplementary Table 4, DAWBA in 
Supplementary Table 5, Q-CHAT and M-CHAT/-R in Supplementary Table 6, RBS-R in 
Supplementary Table 7, CDI in Supplementary Table 8, Mullen Scales of Early Learning in 
Supplementary Table 9, VABS in Supplementary Table 10, ITSP in Supplementary Table 11, 
IBQ-R in Supplementary Table 12, ECBQ in Supplementary Table 13, and CBCL 1½ -5 in 
Supplementary Table 14. 
A substantial variation was identified in the availability of diagnostic instruments for 
different countries, cultures, or languages (Table 1), with only three regions (UK/Ireland, 
Scandinavia, and Belgium/The Netherlands) having access to sufficiently usable forms of all 
of the 14 diagnostic instruments. Additionally, clinicians and researchers from Israel and 
Portugal have access to 13 out of 14 proposed diagnostic instruments. For four of the 
surveyed countries (Romania, Hungary, FYR Macedonia and Czech Republic) less than half 
of the instruments have been translated or adapted. 
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About here: Table 1 
 
Not surprisingly, the number of instruments being available per country from a 
commercial publisher or directly from the authors of the respective tool in an organized 
fashion (e.g. download from a website) (here called ‘formal distribution’) also varied for 
different languages and countries/regions. In addition, although many of the available 
diagnostic tools are also distributed formally, in most cases, the number of available tools is 
higher than the number of tools distributed formally. The exceptions are UK/Ireland, German 
speaking countries (Germany, Austria, and Switzerland), Spain, Iceland, and Romania in 
which all available tools are even distributed formally. 
Generally, many of the available (and published) diagnostic instruments have not been 
specifically standardized for the different European languages and countries/regions (Table 
1). Even in the regions with high availability of diagnostic instruments, country/language 
specific reliability and validity properties or norms/cut-offs are sparse (e.g. in France, Italy, 
Spain) or missing (e.g. in Israel, Portugal, Finland). German and English speaking countries 
are exceptions from this observation, even though in the UK and Ireland for some tools there 
is a high reliance on generalizability of studies from the USA. If one assumes generalizability 
across English speaking countries, the USA, UK, and Ireland are characterized by the highest 
number of available, formally distributed as well as normalized methods. Dutch speaking 
countries as well as Scandinavian countries are other examples of regions with relatively high 
availability of some usable forms of the diagnostic instruments, which are mostly formally 
distributed. Country/language specific normalization is, however, less common in case of 
these regions. Scientists and clinicians from German speaking countries can formally access 
11 of the proposed diagnostic instruments, for which two thirds have a culture/language 
specific standardization. In the case of other regions, even if translated diagnostic instruments 
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are (formally or informally) available, specific standardizations are lacking. Clinicians and 
scientists from Czech Republic have the most limited access to diagnostic tools for early ASD 
assessment. Only 4 out of 14 tools have been translated to Czech, out of which two are 
formally available but none language specific data has been collected. 
 
About here: Table 2 
 
Table 2 shows the availability of each of the early ASD diagnostic instruments within 
the totality of European languages/cultural regions. The only widely available tool across 
Europe is the ADOS/ADOS-2, which is accessible across all the examined language/culture 
regions. The ADI-R, CBCL, M-CHAT/Q-CHAT and SCQ are available in the majority of 
regions. Nevertheless, there are not very many publications on these relatively well accessible 
methods originating in Europe (see Suppl Tables 1-14 & references). Two instruments are 
particularly infrequently available in Europe: The Mullen Scales of Early Learning and the 
RBS-R (both available in 4 languages/culture regions). Among the formally distributed tools 
available in different language versions from commercial publishers are the ADOS-2 and 
ADI-R. The process of getting both of these published is protracted and takes several years. 
Instruments formally distributed by their authors are the DAWBA, M-CHAT, and 
MacArthur-Bates Communicative Development Inventory. Instruments with poor distribution 
are the ITSP, RBS-R and Mullen Scales of Early Learning. Region/language specific 
standardizations are scarce or missing for many of the early ASD diagnostic instruments. This 
holds true even for tools with greater availability. The CDI can be partially considered an 
exception because it is available in 13 out of 16 examined regions and it has specific norms 
for 7 of the countries. 
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Discussion 
Psychiatric research is based on reliable phenotyping, predominantly ensured by 
psychodiagnostic tools including first choice diagnostic instruments (“gold standard”) to 
determine psychiatric status, general psychopathology or psychological characteristics (e.g. 
neuropsychological functions, IQ). Nevertheless, many of these scales and tests are only 
available in a limited number of languages, and have been normalized and validated for an 
even smaller number of cultural backgrounds. This study examined the (in-)equalities of 
research prerequisites across Europe regarding the access to diagnostic instruments enabling 
internationally competitive research on early ASD identification. Our study suggests that the 
middle-income countries are disadvantaged in Europe. The two included middle-income 
European countries (Romania, FYR Macedonia) had limited access to diagnostic scales 
compared to high-income European countries. In addition, limited access to certain 
instruments was identified in other east European countries (Czech Republic, Hungary, 
Poland) as well as Iceland, a country with a small population and its own language. However, 
even in these countries the access to a smaller selection of ASD specific scales, such as the 
ADOS-2, ADI-R, SCQ or M-CHAT/Q-CHAT or instruments used frequently in international 
research and practice to evaluate general psychopathology (CBCL) was satisfactory. These 
scales are either formally distributed by commercial publishers or freely and systematically 
made available by the authors. A further, less recognized issue in this context is the level of 
availability of each instrument to clinicians as well the availability of adequate clinical and 
research training. In many countries where certain tools are not formally distributed, they 
have been adapted for research purposes only. This means that each administration is subject 
to license fees paid directly to the copyright holder and in result the instrument is not 
available for clinical practice. Thus tool availability is further impounded by the need to 
negotiate license agreements with the publisher of the original version, while the publisher 
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often sets a number of limitations on the use of data collected with this instrument. This is a 
particularly sensitive issue in the face of increasing demands for free access to research data 
put forward by public research funding bodies. As the purpose of this mapping was to 
examine if European countries can adhere to internationally competitive research protocols 
(www.eu-aims.eu; www.eurosibs.eu), not the usage of ASD diagnostics in European clinical 
practice, we did not examine frequencies of usage of the various instruments in relation to 
either commercial or free distribution. We are therefore unable to evaluate which of the two is 
generally more beneficial for accessibility and usage. The latter is surely a limitation of the 
current study, and deserves more attention in future research. It is of paramount interest to the 
EU-AIMS project mentioned earlier, and strategies and actions to solve related obstacles in 
Europe have been recently described (Ashwood, Buitelaar, Murphy, Spooren, & Charman, 
2014). Still, as commercially distributed instruments are associated with costs for purchase, 
which are often high for LAMI countries, and entail stricter rules for copyright and terms of 
usage, free access is probably more advisable to reduce inequalities of research prerequisites 
concerning instrument access. However, even free access might not solve other challenges for 
LAMI countries, such as limited access to (expensive) training to ensure quality control of 
administration, scoring and interpretation, like currently required for the ADOS-2 and ADI-R. 
Strikingly, we found that for all European languages/cultural regions, no matter high 
or middle income, small or large population and rare or frequently spoken language, there was 
a substantial deficiency of adequate language/cultural standardization. The only language for 
which standardization was sufficient across instruments was English (UK/Ireland), but only 
when assuming high intercultural validity between these countries and USA. Most scales 
originate from the USA, and generalizability of psychometric properties and norms to high 
income European countries is often assumed. However, several studies, for instance those 
from Germany or Sweden on the ADOS-2, ADI-R or SRS show that this is only partially true 
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(Bölte & Poustka, 2004; Bölte, Poustka, & Constantino, 2008; Zander et al., 2014). The latter 
demonstrates the need for increased cross-cultural research in the field of psychometric 
evaluation, an extremely and continuously underfunded area of science. This is unfortunate, 
as a large part of psychiatric research of all kind is based on reliable phenotyping, 
predominantly ensured by psychodiagnostic tools. 
Reasons for international research imbalances in terms of tool availability and other 
aspects are multifaceted. Proximal causes include the fact that the amount of research 
conducted in LAMI countries is comparably small and more likely to be of lower scientific 
quality than in high-income countries (Alem & Kebede, 2003). There are extremely few 
research skilled psychiatrists, clinical psychologists and other mental health professionals, and 
those who are, mostly work clinically, with a strong need to focus on health care services. 
Researchers face difficult circumstances in LAMI countries, owing to social, political and 
economic situations that do not or cannot prioritize psychiatry research, leading to a lack of 
funding, poor equipment, and inadequate education. Moreover, a low level of scientific 
culture with no research and publication tradition hampers research (Jablensky, 1999). Our 
study also points out research disadvantages in developed countries with small populations 
and rarely spoken languages (e.g. Iceland). This is an obvious challenge, but it has rarely been 
discussed previously in the literature. 
The underrepresentation of certain countries, especially LAMI countries in psychiatry 
research is both ethically and scientifically challenging. Ethically, The World Mental Health 
report has pointed-out the immense burden of psychiatric problems and disability that are 
associated with mental disorders in LAMI countries (Desjarlais, 1996), and the research gap 
also reflects the well-known 10/90 global divide: less than 10% of the world's research 
resources are earmarked for more than 90% of the health problems (The 10/90 report on 
health research 2000). Scientifically, it is reasonable to support the use of the research 
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capacities and findings from LAMI countries. Their inclusion might reduce research and 
publication bias, by providing a lot broader perspective on mental health and possibly new 
significant insights into basic and applied psychiatry. To a lesser degree this might even be 
true for developed countries, with small populations or rarely spoken languages. 
To increase underrepresented countries, collaborative research between LAMI and 
more scientifically established countries is fruitful (Doku & Mallett, 2003). Several 
international collaborations have previously raised awareness for inequalities in psychological 
and psychiatric research prerequisites including the availability of scales to assess child 
development. For instance, The World Psychiatric Association (WPA) Task Force, initiated 
activities aiming to support psychiatry journals (e.g. with PubMed indexation) in LAMI 
countries (de Jesus Mari et al., 2009), the Grand Challenges in Global Mental Health initiative 
by the US National Institute of Mental Health has identified research priorities to impact on 
mental health internationally (Collins et al., 2011), The WHO-launched collaborative 
longitudinal study of schizophrenia (Padma, 2014), and the Grand Challenges in Global 
Mental Health initiatives (Collins et al., 2011) aim to disclose overseen obstacles for 
international psychiatric research. In terms of diagnostic tool availability, The Etiology, Risk 
Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for 
Child Health and Development (MAL-ED) cohort study (Murray-Kolb et al., 2014). Across 8 
sites, in Bangladesh, Brazil, India, Nepal, Pakistan, Peru, South Africa, and Tanzania, the 
Bayley Scales of Infant and Toddler Development and a modified MacArthur Communicative 
Development Inventory were adapted. Herein, the authors explicitly point-out the complexity 
and costs of worldwide psychodiagnostic tool harmonization, in order to raise awareness 
among funders for future research support in this area of science. 
The current mapping study is the first to review lacking diagnostic scale availability in 
early assessment of childhood ASD for research purposes from a cross-national perspective. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Psychodiagnostic tool availability in autism 
 
 15 
Initiatives such as COST-ESSEA, and outcomes from these initiatives, such as the present 
study, can help to generate awareness of research inequalities in ASD and other 
neurodevelopmental disorders. They might serve as a decision pad for policy makers and the 
international research community to overcome those inequalities. Future studies in the area 
should investigate the status quo of tool availability in ASD beyond Europe, also include 
scales for adolescent and adult ASD, and also incorporate research prerequisites in relation 
clinical practice. 
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Challenges and inequalities of opportunities in European psychiatry research: 
The example of psychodiagnostic tool availability in 
research on early autism identification 
 
Summary 
Background: Europe is diverse in terms of economy, cultures, socio-demography and 
languages. A crucial aspect of psychiatric research is the availability of standardized 
screening, diagnostic and characterization instruments. Aims/Method: We fine-mapped the 
accessibility of 14 clinical scales and cognitive tests for the assessment of early childhood 
autism spectrum disorder [ASD] (e.g. ADOS, ADI-R, SCQ, SRS, CHAT, MESL) within 21 
European countries. These tools are essential for internationally competitive early ASD 
detection research. Results: We identified a considerable variation not only in the availability, 
but also psychometric standardization, and formal distribution of the instruments between the 
countries, privileging English speaking, high-income and highly populated European 
countries. Absence of country-specific standardization was a problem across many countries, 
independent of income and size. Discussion: Findings demonstrate, on a concrete level, the 
challenges in creating equal early ASD identification research opportunities in Europe, and 
the need for increased funding for instrument development and validation. We discuss the 
reasons, implications and consequences of this inequity and ways of reducing it. 
 
Key Words: Assessment, neurodevelopmental disorders, mental health, tests, 
psychometrics 
 
 
Manuscript clean
Click here to download Manuscript: aut_COST_ScaleMapp__Revision 2_clean.docx 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Psychodiagnostic tool availability in autism 
 
 2 
Introduction 
Europe is diverse in terms of cultures and languages, comprising 53 countries 
according to the WHO definition (including parts of geographical Asia), of which 28 are 
currently organized under the European Union (EU). Although many European countries are 
developed high-income countries, this should not camouflage the huge differences between 
high and less developed countries. For instance, following the World Bank’s (worldbank.org) 
2013/14 classification of low and middle income (LAMI) countries, a noteworthy number of 
17 European countries are still judged as low-middle (e.g. Albania, Georgia, Moldova, 
Ukraine) or upper-middle income (e.g. Bulgaria, FYR Macedonia, Romania, Turkey), of 
which 4 are EU countries. Clinical and research psychiatry is equally diverse across Europe, 
with substantial variations even within countries due to federalism or regionalization (Evans-
Lacko et al., 2014; Muijen, 2012). As for the world-wide situation, research output in Europe 
is dominated by the high-income countries (Muijen, 2012; Sumathipala et al., 2004). 
ASD is a neurodevelopmental condition defined by overarching impairments in the 
areas of reciprocal social communication and interaction, alongside a preference for 
repetitive, stereotyped activities, patterns of behaviors and interests (Bölte & Hallmayer, 
2011). ASD has emerged a top priority health care issue in many countries (see for instance 
USA: “Combating Autism Act of 2006”, “Autism Treatment Acceleration ACT of 2009”; or 
UK: Autism Act UK, 2009) because of increasing rates of diagnoses (in high income 
countries) around the globe (Elsabbagh et al., 2012), as well as high associated societal 
challenges and costs (Gustavsson et al., 2011) of educational and clinical care. In recent years, 
a growing interest in early detection of ASD has emerged, mostly driven by the insight that 
early identification is a prerequisite for early intervention, which itself may improve long-
term outcomes for individuals with ASD (Dawson, 2008). Several methodologies have helped 
to investigate early detection and intervention in ASD, in particular screening studies and 
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research on high-risk siblings (Bölte et al., 2013; Garcia-Primo et al., 2014; Ozonoff et al., 
2011). 
The availability of standardized diagnostic instruments is a crucial prerequisite for 
conducting high-quality early ASD detection research. Without evidence-based standardized 
phenotyping in psychiatry there is a risk of diagnostic bias and “garbage in, garbage out” 
research. Significant progress has been made over the past two decades in the development of 
reliable and valid phenotyping tools for ASD (Charman & Gotham, 2013). Many of these 
instruments are part of national or regional clinical guidelines for ASD in European countries 
(Arngrim et al., 2013; "Autism diagnosis in children and young people. Recognition, referral 
and diagnosis of children and young people on the autism spectrum,"), while some are viewed 
as a “gold standard”, most notably the Autism Diagnostic Observation Schedule, Second 
Edition (Hus, Gotham, & Lord, 2012) combined with the Autism Diagnostic Interview- 
Revised (Rutter, Le Couteur, & Lord, 2003). Publication of ASD research findings in leading 
ASD or general psychiatry journals can be challenging or even impossible without these tools. 
Nevertheless, their availability, validation and standardization are limited to a small group of 
languages and cultures. The latter substantially limits international collaboration, and research 
opportunities for many countries, even in Europe, perhaps particularly for the LAMI countries 
among them. 
The goal of this study was to inventory the accessibility and standardization of 
diagnostic instruments for early identification of autism across 21 European countries. 
Instruments were mapped that are currently required for internationally competitive early 
ASD identification research. With this work we aim to highlight potential challenges and (in-
)equalities of science opportunities across Europe in a concrete manner. The findings might 
be valuable to further raise awareness of research barriers in Europe and beyond, and to direct 
the focus of international public policy on these issues. This is particularly important for 
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LAMI countries, but also for less populated countries and those with less commonly spoken 
languages. 
 
Methods 
Participants and procedure 
The study was carried-out between November 2013 and April 2014. Twenty-one 
European countries involved in the COST (European Cooperation in Science and Technology; 
www.cost.eu) action “Enhancing the Scientific Study of Early Autism” (ESSEA; for details 
see www.cost-essea.com) participated. COST-ESSEA is a network of over 60 scientists from 
23 European countries, including three LAMI countries (Romania, FYR Macedonia, and 
Turkey), intending to develop capacity in early autism research across all action members. 
The principal investigators or research groups’ contact persons for each of the COST ESSEA 
research network countries were surveyed. They were the official COST ESSEA management 
committee representatives for their countries1, chosen by the chair, vice chair and the four 
working group leaders of the action based when a country entered the network based on 
documented scientific experience and excellence in the area of early ASD assessment 
research. The countries were partly clustered for the study to form 16 language/cultural 
groups that in practice usually use the same versions of adapted diagnostic tools: 
Austria/Germany/Switzerland (German), Belgium/The Netherlands (Dutch), Czech Republic, 
Finland, France (including information on French-Canadian adaptations of tools), Hungary, 
Iceland, Italy, Israel, Macedonia, Poland, Portugal (including information on Brazilian 
adaptations of tools), Spain, Sweden/Norway (Scandinavia), Romania, and UK/Ireland 
(English; even US-versions of instruments included here). Excel spreadsheet inventories 
containing items about the availability and standardization of language/culturally adapted 
                                                          
1 See: https://e-services.cost.eu/w3/index.php?id=1627&action_number=BM1004 
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versions of diagnostic instruments often used in leading research on early ASD identification 
were generated. They included 4 items: (1) Existence of domestic (language) versions of the 
instruments, (2) Domestic psychometric data (norms, reliability, validity) published, (3) 
Copyright for the instrument, (4) Published studies, on each of the 14 scales/tests (see section 
“inventoried instruments” below). The spreadsheets were sent via e-mail to the principal 
investigators or research groups’ contact persons and returned electronically. The returned 
material was analyzed, missing or inconsistent data was added or corrected by the authors 
based on own knowledge, searches in existing databases (e.g. Pubmed, PsychInfo), 
correspondence with publishers as well the original authors of the mapped diagnostic tools, 
and summarized to form an overview on the availably of the clinical scales and psychological 
tests across the 16 language/cultural groups. Finally, the overview was sent to the informants 
for approval. Before submission (December 2014) of this article some information was 
updated to include the most recent developments. 
The selection of early ASD diagnostic instruments was based on a research protocol 
developed within “European Autism Interventions - A Multicentre Study for Developing New 
Medications (EU-AIMS; www.eu-aims.eu). Herein, and using Delphi method, leading 
European labs of ASD research have agreed on a common protocol of 14 clinical scales and 
psychological tests currently deemed the most adequate ones for research on early ASD 
detection, owing to their scientific quality, as well as scientific and clinical usage from an 
international perspective. An overview of this shared protocol is available online 
(www.eurosibs.eu), and the strategic concepts of EU-AIMS in terms of assessments and 
patient characterization are described elsewhere in detail (Ashwood, Buitelaar, Murphy, 
Spooren, & Charman, 2014). The instruments are briefly introduced in the following section. 
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Inventoried instruments 
ASD-specific scales. (1) The Autism Diagnostic Observation Schedule, Second 
Edition (ADOS-2) is a play and interview-based observation scale administered by 
experienced and specifically trained clinicians operationalizing DSM-IV/DSM-5 criteria for 
ASD in an empirically derived diagnostic algorithm. Different modules of the instrument are 
applied depending on the individual’s age and expressive language level. Module T (for 
toddlers; no speech to single phrases, age 12-30 months) and module 1 (no speech to single 
phrases, >31 months of age to school age) are most relevant to early ASD assessment 
research; (2) The Autism Diagnostic Interview-Revised (ADI-R) is an investigator-based 
structured diagnostic caregiver interview, also operationalizing DSM-IV/DSM-5 criteria for 
ASD in a diagnostic algorithm. It can be used for individuals with suspected ASD of any age, 
although it is preferably used for children and adolescents. Recently, specific ADI-R 
diagnostic algorithms for toddlers and preschoolers have been published (Kim, Thurm, 
Shumway, & Lord, 2013). The combined use of the ADI-R and ADOS is often viewed as the 
first choice of diagnosing ASD in research and practice. This is true even for early ASD 
assessments (Zander, Sturm, & Bölte, 2014); (3) The Social Communication Questionnaire 
(SCQ) is a parent-report clinical ASD screener derived from the ADI-R. There are two 
versions: the “current” and the “lifetime” version; (4) The Social Responsiveness Scale (SRS) 
is a parent or teacher report questionnaire of autism traits for children aged 4-18 years. The 
preschool version of the SRS (SRS-P) covers the age range of 3 to 4 years; (5) The 
Development and Well-Being Assessment (DAWBA) is a group of interviews, questionnaires 
and rating scales to enable ICD-10/DSM-IV psychiatric diagnoses on 5-17 year olds; 
DAWBA results can be inserted into a computer program algorithm that generates 
probabilities for a range of psychiatric disorders, including ASD. The provisional computer-
generated diagnoses are then reviewed by an expert clinician; (6) The Quantitative (Q)-CHAT 
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 7 
and the Modified (M)-CHAT/-Revised are early parent-report ASD screeners for young 
children aged between 16/18 to 24/30 months of age; (7) The Repetitive Behavior Scale 
(RBS) is a questionnaire that captures the breadth of stereotypic behaviors in individuals of 
any age with ASD on five dimensions, namely ritualistic/sameness behavior, stereotypic 
behavior, self-injurious behavior, compulsive behavior, and restricted interests. For 
comprehensive references see “Supplementary Materials”. 
Non ASD-specific psychological tests and clinical scales. (8) The MacArthur-Bates 
Communicative Development Inventory (CDI) is a parent-/caregiver report tool for assessing 
language and communication development in infants and children. In most versions, it comes 
in two scales, an infant (8 to 16 months), and a toddler scale (16 to 30 months), capturing 
comprehension, word production and aspects of symbolic and communicative gesture, word 
production and the early grammar. Short screening version exists for English and Spanish and 
several other languages; (9) The Mullen Scales of Early Learning is a clinician administered 
child development test to measure gross and fine motor, visual reception, and expressive and 
receptive language from birth to 68 months of age; (10) The Vineland Adaptive Behavior 
Scales (VABS) is a parent/caregiver report measure (administered as either a questionnaire or 
a clinical interview) of adaptive function in everyday life regarding social, communicative, 
daily living and motor skills (up to 6 years) from birth onwards; (11) The Infant-Toddler 
Sensory Profile (ITSP) is a parent/caregiver questionnaire on sensory processing patterns in 
infants (0-6 months) and toddlers (7-36 months), quantifying five domains: auditory, visual, 
tactile, vestibular, and oral sensory processing; (12) The Infant Behavior Questionnaire-
Revised (IBQ-R) is a parent rated measure of infant temperament (3-12 months) on 14 
subscales (e.g. activity level, distress to limitations, fear, smiling/laughter, cuddliness). Short 
and very short versions exist; (13) The Early Childhood Behavior Questionnaire (ECBQ) 
serves the same purpose as the IBQ-R, but in young children aged 18 and 36 months. It 
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ECBQ assesses 18 dimensions of temperament (e.g. attentional focus, cuddliness, discomfort, 
frustration, impulsivity, shyness); (14) The Child Behavior Checklist (CBCL) 1½ -5 is an 
assessment of general problem behaviors in preschool children. The information is obtained 
from parents or teachers using items on eight syndrome scales (emotionally reactive; 
anxious/depressed; somatic complaints; withdrawn; sleep problems, attention problems; rule-
breaking behavior; aggressive behavior). For comprehensive references see “Supplementary 
Materials”. 
 
Results 
A detailed description of adaptations available for each of the reviewed scales or tests 
per country / linguistic region is provided in the supplementary tables and references (Suppl. 
Tables 1-14 & references): ADOS in Supplementary Table 1, ADI-R in Supplementary Table 
2, SCQ in Supplementary Table 3, SRS in Supplementary Table 4, DAWBA in 
Supplementary Table 5, Q-CHAT and M-CHAT/-R in Supplementary Table 6, RBS-R in 
Supplementary Table 7, CDI in Supplementary Table 8, Mullen Scales of Early Learning in 
Supplementary Table 9, VABS in Supplementary Table 10, ITSP in Supplementary Table 11, 
IBQ-R in Supplementary Table 12, ECBQ in Supplementary Table 13, and CBCL 1½ -5 in 
Supplementary Table 14. 
A substantial variation was identified in the availability of diagnostic instruments for 
different countries, cultures, or languages (Table 1), with only three regions (UK/Ireland, 
Scandinavia, and Belgium/The Netherlands) having access to sufficiently usable forms of all 
of the 14 diagnostic instruments. Additionally, clinicians and researchers from Israel and 
Portugal have access to 13 out of 14 proposed diagnostic instruments. For four of the 
surveyed countries (Romania, Hungary, FYR Macedonia and Czech Republic) less than half 
of the instruments have been translated or adapted. 
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About here: Table 1 
 
Not surprisingly, the number of instruments being available per country from a 
commercial publisher or directly from the authors of the respective tool in an organized 
fashion (e.g. download from a website) (here called ‘formal distribution’) also varied for 
different languages and countries/regions. In addition, although many of the available 
diagnostic tools are also distributed formally, in most cases, the number of available tools is 
higher than the number of tools distributed formally. The exceptions are UK/Ireland, German 
speaking countries (Germany, Austria, and Switzerland), Spain, Iceland, and Romania in 
which all available tools are even distributed formally. 
Generally, many of the available (and published) diagnostic instruments have not been 
specifically standardized for the different European languages and countries/regions (Table 
1). Even in the regions with high availability of diagnostic instruments, country/language 
specific reliability and validity properties or norms/cut-offs are sparse (e.g. in France, Italy, 
Spain) or missing (e.g. in Israel, Portugal, Finland). German and English speaking countries 
are exceptions from this observation, even though in the UK and Ireland for some tools there 
is a high reliance on generalizability of studies from the USA. If one assumes generalizability 
across English speaking countries, the USA, UK, and Ireland are characterized by the highest 
number of available, formally distributed as well as normalized methods. Dutch speaking 
countries as well as Scandinavian countries are other examples of regions with relatively high 
availability of some usable forms of the diagnostic instruments, which are mostly formally 
distributed. Country/language specific normalization is, however, less common in case of 
these regions. Scientists and clinicians from German speaking countries can formally access 
11 of the proposed diagnostic instruments, for which two thirds have a culture/language 
specific standardization. In the case of other regions, even if translated diagnostic instruments 
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are (formally or informally) available, specific standardizations are lacking. Clinicians and 
scientists from Czech Republic have the most limited access to diagnostic tools for early ASD 
assessment. Only 4 out of 14 tools have been translated to Czech, out of which two are 
formally available but none language specific data has been collected. 
 
About here: Table 2 
 
Table 2 shows the availability of each of the early ASD diagnostic instruments within 
the totality of European languages/cultural regions. The only widely available tool across 
Europe is the ADOS/ADOS-2, which is accessible across all the examined language/culture 
regions. The ADI-R, CBCL, M-CHAT/Q-CHAT and SCQ are available in the majority of 
regions. Nevertheless, there are not very many publications on these relatively well accessible 
methods originating in Europe (see Suppl Tables 1-14 & references). Two instruments are 
particularly infrequently available in Europe: The Mullen Scales of Early Learning and the 
RBS-R (both available in 4 languages/culture regions). Among the formally distributed tools 
available in different language versions from commercial publishers are the ADOS-2 and 
ADI-R. The process of getting both of these published is protracted and takes several years. 
Instruments formally distributed by their authors are the DAWBA, M-CHAT, and 
MacArthur-Bates Communicative Development Inventory. Instruments with poor distribution 
are the ITSP, RBS-R and Mullen Scales of Early Learning. Region/language specific 
standardizations are scarce or missing for many of the early ASD diagnostic instruments. This 
holds true even for tools with greater availability. The CDI can be partially considered an 
exception because it is available in 13 out of 16 examined regions and it has specific norms 
for 7 of the countries. 
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Discussion 
Psychiatric research is based on reliable phenotyping, predominantly ensured by 
psychodiagnostic tools including first choice diagnostic instruments (“gold standard”) to 
determine psychiatric status, general psychopathology or psychological characteristics (e.g. 
neuropsychological functions, IQ). Nevertheless, many of these scales and tests are only 
available in a limited number of languages, and have been normalized and validated for an 
even smaller number of cultural backgrounds. This study examined the (in-)equalities of 
research prerequisites across Europe regarding the access to diagnostic instruments enabling 
internationally competitive research on early ASD identification. Our study suggests that the 
middle-income countries are disadvantaged in Europe. The two included middle-income 
European countries (Romania, FYR Macedonia) had limited access to diagnostic scales 
compared to high-income European countries. In addition, limited access to certain 
instruments was identified in other east European countries (Czech Republic, Hungary, 
Poland) as well as Iceland, a country with a small population and its own language. However, 
even in these countries the access to a smaller selection of ASD specific scales, such as the 
ADOS-2, ADI-R, SCQ or M-CHAT/Q-CHAT or instruments used frequently in international 
research and practice to evaluate general psychopathology (CBCL) was satisfactory. These 
scales are either formally distributed by commercial publishers or freely and systematically 
made available by the authors. A further, less recognized issue in this context is the level of 
availability of each instrument to clinicians as well the availability of adequate clinical and 
research training. In many countries where certain tools are not formally distributed, they 
have been adapted for research purposes only. This means that each administration is subject 
to license fees paid directly to the copyright holder and in result the instrument is not 
available for clinical practice. Thus tool availability is further impounded by the need to 
negotiate license agreements with the publisher of the original version, while the publisher 
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often sets a number of limitations on the use of data collected with this instrument. This is a 
particularly sensitive issue in the face of increasing demands for free access to research data 
put forward by public research funding bodies. As the purpose of this mapping was to 
examine if European countries can adhere to internationally competitive research protocols 
(www.eu-aims.eu; www.eurosibs.eu), not the usage of ASD diagnostics in European clinical 
practice, we did not examine frequencies of usage of the various instruments in relation to 
either commercial or free distribution. We are therefore unable to evaluate which of the two is 
generally more beneficial for accessibility and usage. The latter is surely a limitation of the 
current study, and deserves more attention in future research. It is of paramount interest to the 
EU-AIMS project mentioned earlier, and strategies and actions to solve related obstacles in 
Europe have been recently described (Ashwood, Buitelaar, Murphy, Spooren, & Charman, 
2014). Still, as commercially distributed instruments are associated with costs for purchase, 
which are often high for LAMI countries, and entail stricter rules for copyright and terms of 
usage, free access is probably more advisable to reduce inequalities of research prerequisites 
concerning instrument access. However, even free access might not solve other challenges for 
LAMI countries, such as limited access to (expensive) training to ensure quality control of 
administration, scoring and interpretation, like currently required for the ADOS-2 and ADI-R. 
Strikingly, we found that for all European languages/cultural regions, no matter high 
or middle income, small or large population and rare or frequently spoken language, there was 
a substantial deficiency of adequate language/cultural standardization. The only language for 
which standardization was sufficient across instruments was English (UK/Ireland), but only 
when assuming high intercultural validity between these countries and USA. Most scales 
originate from the USA, and generalizability of psychometric properties and norms to high 
income European countries is often assumed. However, several studies, for instance those 
from Germany or Sweden on the ADOS-2, ADI-R or SRS show that this is only partially true 
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(Bölte & Poustka, 2004; Bölte, Poustka, & Constantino, 2008; Zander et al., 2014). The latter 
demonstrates the need for increased cross-cultural research in the field of psychometric 
evaluation, an extremely and continuously underfunded area of science. This is unfortunate, 
as a large part of psychiatric research of all kind is based on reliable phenotyping, 
predominantly ensured by psychodiagnostic tools. 
Reasons for international research imbalances in terms of tool availability and other 
aspects are multifaceted. Proximal causes include the fact that the amount of research 
conducted in LAMI countries is comparably small and more likely to be of lower scientific 
quality than in high-income countries (Alem & Kebede, 2003). There are extremely few 
research skilled psychiatrists, clinical psychologists and other mental health professionals, and 
those who are, mostly work clinically, with a strong need to focus on health care services. 
Researchers face difficult circumstances in LAMI countries, owing to social, political and 
economic situations that do not or cannot prioritize psychiatry research, leading to a lack of 
funding, poor equipment, and inadequate education. Moreover, a low level of scientific 
culture with no research and publication tradition hampers research (Jablensky, 1999). Our 
study also points out research disadvantages in developed countries with small populations 
and rarely spoken languages (e.g. Iceland). This is an obvious challenge, but it has rarely been 
discussed previously in the literature. 
The underrepresentation of certain countries, especially LAMI countries in psychiatry 
research is both ethically and scientifically challenging. Ethically, The World Mental Health 
report has pointed-out the immense burden of psychiatric problems and disability that are 
associated with mental disorders in LAMI countries (Desjarlais, 1996), and the research gap 
also reflects the well-known 10/90 global divide: less than 10% of the world's research 
resources are earmarked for more than 90% of the health problems (The 10/90 report on 
health research 2000). Scientifically, it is reasonable to support the use of the research 
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capacities and findings from LAMI countries. Their inclusion might reduce research and 
publication bias, by providing a lot broader perspective on mental health and possibly new 
significant insights into basic and applied psychiatry. To a lesser degree this might even be 
true for developed countries, with small populations or rarely spoken languages. 
To increase underrepresented countries, collaborative research between LAMI and 
more scientifically established countries is fruitful (Doku & Mallett, 2003). Several 
international collaborations have previously raised awareness for inequalities in psychological 
and psychiatric research prerequisites including the availability of scales to assess child 
development. For instance, The World Psychiatric Association (WPA) Task Force, initiated 
activities aiming to support psychiatry journals (e.g. with PubMed indexation) in LAMI 
countries (de Jesus Mari et al., 2009), the Grand Challenges in Global Mental Health initiative 
by the US National Institute of Mental Health has identified research priorities to impact on 
mental health internationally (Collins et al., 2011), The WHO-launched collaborative 
longitudinal study of schizophrenia (Padma, 2014), and the Grand Challenges in Global 
Mental Health initiatives (Collins et al., 2011) aim to disclose overseen obstacles for 
international psychiatric research. In terms of diagnostic tool availability, The Etiology, Risk 
Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for 
Child Health and Development (MAL-ED) cohort study (Murray-Kolb et al., 2014). Across 8 
sites, in Bangladesh, Brazil, India, Nepal, Pakistan, Peru, South Africa, and Tanzania, the 
Bayley Scales of Infant and Toddler Development and a modified MacArthur Communicative 
Development Inventory were adapted. Herein, the authors explicitly point-out the complexity 
and costs of worldwide psychodiagnostic tool harmonization, in order to raise awareness 
among funders for future research support in this area of science. 
The current mapping study is the first to review lacking diagnostic scale availability in 
early assessment of childhood ASD for research purposes from a cross-national perspective. 
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Initiatives such as COST-ESSEA, and outcomes from these initiatives, such as the present 
study, can help to generate awareness of research inequalities in ASD and other 
neurodevelopmental disorders. They might serve as a decision pad for policy makers and the 
international research community to overcome those inequalities. Future studies in the area 
should investigate the status quo of tool availability in ASD beyond Europe, also include 
scales for adolescent and adult ASD, and also incorporate research prerequisites in relation 
clinical practice. 
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Table 1. Total number of assessment tools (out of 14 examined in this review) available in 
each of the 16 language/cultural groups. 
 
Region Availability Standardization Formal distribution 
UK, Ireland 14 9 (1)* 14 
Scandinavia 14 5 13 
Belgium, The Netherlands 14 7 12 
Israel 13 0 11 
Portugal 13 0 8 
France 12 3 11 
Finland 12 0 11 
Germany, Austria, 
Switzerland 
11 8 11 
Italy 11 3 9 
Spain 11 4 11 
Poland 9 1 8 
Iceland 8 1 8 
Romania 6 0 6 
Hungary 6 0 5 
Macedonia 5 1 3 
Czech Republic 4 0 2 
 
Note. Column “availability” summarizes the total number of assessment tools for which a language version 
exists; column “standardization” shows how many of those language specific versions have country specific 
psychometrics; column “formal distribution” contains information regarding the number of psychological 
assessment tools which are formally distributed (by a publisher or the authors of the method) per 
language/cultural group 
* Number in brackets indicates the number of assessment tools with UK, Ireland standardization (other value 
includes USA specific normalizations). 
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Table 2. Availability of each of the assessment tools per language/culture groups. 
 
 Availability Standardization Formal 
distribution 
ADOS 16 3 14 
ADI-R 15 4 13 
CBCL 15 3 14 
CHAT 14 3 12 
SCQ 14 2 13 
CDI 13 7 13 
DAWBA 13 1 13 
VABS 12 4 11 
IBQ-R 12 3 12 
ECBQ-R 11 0 11 
SRS 11 3 8 
ITSP 9 1 5 
RBS-R 4 0 1 
MSEL 4 0 3 
Note. ASD-specific scales are marked with bold italics. Column “availability” indicates the number of 
language/culture groups for which a given method is available; column “standardization” specifies in how many 
of the assessed language/culture groups the diagnostic instrument has been specifically standardized; column 
“formal distribution” specifies in how many of the assessed language/culture groups the diagnostic instrument is 
formally distributed (by a publisher or the authors of the method). 
ADOS = Autism Diagnostic Observation Schedule, ADI-R = Autism Diagnostic Interview-Revised, CBCL = 
Child Behavior Checklist,  CHAT = Modified Checklist for Autism in Toddlers, SCQ = Social Communication 
Questionnaire, CDI = McArthur-Bates Communicative Development Inventory, DAWBA = Development and 
Well-Being Assessment, VABS = Vineland Adaptive Behavior Scales, IBQ-R = Infant Behavior Questionnaire 
– Revised, ECBQ-R = Early Childhood Behavior Questionnaire, SRS = Social Responsiveness Scale, ITSP = 
Infant Toddler Sensory Profile, RBS-R = Repetitive Behavior Scale – Revised, MSEL = Mullen Scales of Early 
Learning. 
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